march 19 tirzepatide Study: produces greater weight loss vs. other GLP-1s FDA Zepbound shortage ends, impacts

The rate of tumour recurrence

Against the backdrop of anticipated double-digit health care cost increases, fueled to a large degree by GLP-1s and overall prescription drug costs, companies cannot ignore the reality that GLP-1s have significant implications for health care budgetsand overall affordability. Further price increases on the horizon With the coming availability of GLP-1 weight loss medications that can be taken orally, 87% of responding employers reported that they expect higher demand from workers, and the vast majority expect the monthly price for prescriptions to only rise

Unfortunately, these warnings may fall short of alerting patients and doctors to the full extent of the risks associated with this drug

Cutting out sugary drinks or reducing meal portions might inadvertently lead to a lack of hydration